Drug Fix: SCOTUS Rules On Generic Skinny Labels, US FDA’s NPV Faces Uncertain Future

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs, as well as Generics Bulletin Executive Editor David Wallace, consider the implications of the US Supreme Court decision upholding the skinny labeling system (:37), including how the generic industry will adapt going forward (9:02). They also discuss the stakeholder comments the US Food and Drug Administration received during a public hearing on the National Priority Voucher and their potential impact on the program’s future (10:50). More On These Topics From The Pink Sheet US Supreme Court Retains Skinny Labeling System, Backs Hikma Over Amarin: Stakeholders Want Clearer Eligibility Criteria For US FDA’s National Priority Voucher Program: NPV Program Facing Legal Durability Questions As Public Meeting Impacting Its Future Approaches: Grading US FDA’s National Priority Voucher Program After One Year: CNPV Public Meeting Questions: US FDA Seeks Talking Points Before Confirming Speakers:

You can listen to Drug Fix: SCOTUS Rules On Generic Skinny Labels, US FDA’s NPV Faces Uncertain Future online on Radio and Podcast. Open the player on this page to stream the available audio.

Drug Fix: SCOTUS Rules On Generic Skinny Labels, US FDA’s NPV Faces Uncertain Future is an episode from Pharma Intelligence Podcasts.

This episode is 28:48 long.

This episode was published on Jun 5, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Pharma Intelligence Podcasts when more episodes are available from the podcast feed.